Immunotherapy targeting the programmed death 1 (PD-1) receptor and its ligand (PD-L1) is also being studied for sarcomas, as are tyrosine kinase inhibitors due to their broad spectrum of inhibitory action on tumour angiogenesis and growth30,31. Here, CD274 is linked to neoplasm.